Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Oxford Immunotec Announces Board Changes

Oxford, UK 27th October 2008 – Oxford Immunotec, Ltd., the world’s leading manufacturer and marketer of T Cell based diagnostic tests announced today that Lawrence Kinet has retired as Chairman of the Company to focus on his new role as CEO of LMA International NV, and that Richard Sandberg has been elected Chairman to fill the vacated position.

Mr. Sandberg was initially appointed as a Director of the Company in 2006. He has significant entrepreneurial and senior management experience in both publicly quoted and private US companies and has played a principal role in starting and building a number of medical diagnostic companies including that of Founder, Chairman, Chief Executive Officer and Chief Financial Officer of DIANON Systems Inc, a publicly traded oncology marketing and database company; Chairman and Chief Financial Officer of Lifecodes Corporation, a pioneer in DNA testing technology; and Chief Financial Officer and Member of the Board of Directors of Matritech Inc (AMEX:MZT), a biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers. He serves on the Board of two other public companies: North American Scientific Inc. (NASDAQ:NASI), a leading innovator of radiation therapy products and systems for treating breast and prostate cancer, and Ethan Allen Interiors Inc. (NYSE:ETH), an international manufacturer and retailer of fine home furnishings.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec, commented, “I would like to thank Lawrence for his exceptional leadership of the Company during a period of considerable change. He has helped steer us through substantial growth and development, culminating in the recent FDA approval of our lead product, T-SPOT.TB. Everyone at Oxford Immunotec is deeply appreciative of his years of service and wish him well in his new venture.”